Rürup B, Schulz J
Z Alternsforsch. 1986 May-Jun;41(3):135-7.
Starting from the fact that during the first days the mortality is essentially determined by the degree of severity of the infarction and its complications, a particularly critical evaluation of the results is required. Patients with a bad prognosis usually have contra-indications for the application of beta-blockers during that phase. After the early complications have been overcome, the obtained findings are much easier to interpret in the sense of a therapeutical conception, and they have caused us to make the generalization--observing the contra-indications--to use beta-blockers in the framework of a complex therapy of myocardial infarction wherever it is possible. The results obtained require further verification, but justify, however, optimism on their part.
鉴于在最初几天死亡率主要由梗死的严重程度及其并发症决定，因此需要对结果进行特别严格的评估。预后不良的患者在此阶段通常有使用β受体阻滞剂的禁忌证。在克服早期并发症后，从治疗理念的角度来看，所获得的结果更容易解释，而且这些结果促使我们得出这样的普遍结论——在遵守禁忌证的情况下——尽可能在心肌梗死的综合治疗框架内使用β受体阻滞剂。所获得的结果需要进一步验证，但尽管如此，这些结果还是让我们有理由保持乐观。
